Background. The disease state of the nephrotic syndrome is characterized by abnormal renal sodium retention that cannot be completely explained by a secondary hyperaldosteronism for the following reasons. Firstly, in rats an enhanced sodium retention is observed before proteinuria with intravascular volume depletion occurs. Secondly, in patients with the nephrotic syndrome, volume expansion with hypertension has been reported despite suppression of the renin-aldosterone system. Therefore, another mechanism for sodium retention must be postulated for this disease state. We hypothesize that this mechanism is a reduced 11b-hydroxysteroid dehydrogenase 2 (11b-HSD2) activity, a phenomenon known to cause enhanced access of cortisol or corticosterone to the mineralocorticoid receptor. Methods. We assessed the 11b-HSD activity by measuring the urinary ratio of tetrahydrocorticosterone (THB) plus 5a-tetrahydrocorticosterone (5a-THB) to 11-dehydro-tetrahydrocorticosterone (THA) by gas chromatography-mass spectrometry in rats with puromycin aminonucleoside (PAN)-induced proteinuria and with adriamycin nephrosis. Furthermore, the plasma ratios of corticosterone to 11-dehydrocorticosterone were measured. Results. The urinary ratio of (THBq5a-THB)uTHA increased in all animals following injection of PAN or adriamycin, indicating a reduced activity of 11b-HSD. The reduced activity of 11b-HSD was confirmed by an increased plasma ratio of corticosterone to 11-dehydrocorticosterone. The changes in the glucocorticoid metabolite ratios were already present before significant proteinuria appeared. Conclusion. PAN-or adriamycin-treated rats develop proteinuria with a reduced activity of 11b-HSD, a mechanism contributing to the abnormal sodium retention in nephrotic syndrome.
Introduction
11b-Hydroxysteroid dehydrogenase (11b-HSD) enzymes catalyse the interconversion of endogenous or exogenous biologically active 11b-hydroxy-glucocorticosteroids (cortisol, corticosterone or prednisolone) into inactive keto-glucocorticosteroids (cortisone, 11-dehydrocorticosterone or prednisone, respectively) w1-4x. Currently two isoenzymes, 11b-HSD1 and 11b-HSD2 accounting for 11b-HSD activity have been cloned and characterized. The enzymes only share a 14% homology and have different physiological roles, regulation, and tissue distribution. 11b-HSD1 acts predominantly as a reductase in vivo, is localized in the endoplasmic reticulum membrane with a luminal orientation of the catalytic domain, is NADP-dependent, has a K m in the micromolar range, and is expressed in most tissues. Its biological relevance is thought to be as the catalyst for the reactivation of cortisone to cortisol, and by that mechanism might regulate glucocorticosteroid access to glucocorticosteroid receptors w4-7x. 11b-HSD2 on the other hand displays 11b-oxidase activity, is localized in the endoplasmatic reticulum membrane with a cytoplasmatic orientation of the catalytic domain, is NAD-dependent, has a nanomolar K m and is preferentially found in tissues expressing mineralocorticoid receptors, including the cortical collecting duct of the kidney w4,7-10x. The pivotal role of 11b-HSD2 in excluding endogenous glucocorticoids from the mineralocorticoid receptor is now widely accepted.
A reduced activity of 11b-HSD2 causes renal sodium retention w11x. There is growing evidence that such a down-regulation of 11b-HSD2 accounts, at least partly, for abnormal sodium retention in disease states such as liver cirrhosis w12,13x. Furthermore, we recently showed that patients with the nephrotic syndrome have a reduced urinary ratio of tetrahydrocortisol (THF) plus 5a-tetrahydrocortisol (5a-THF) to 11-dehydrotetrahydrocortisone (THE), suggesting a diminished activity of 11b-HSD2 w14x. The 29 nephrotic patients investigated were treated with a variety of different drugs that might interfere with 11b-HSD2 activity, and exhibited seven different underlying disease states causing the nephrotic syndrome. Therefore, to show unambiguously that sodium retention in proteinuric states is associated with a decline in 11b-HSD2 activity, we induced proteinuria by puromycin aminonucleoside (PAN) or adriamycin in rats. We assessed the activity of 11b-HSD2 by measuring the urinary ratio of tetrahydrocorticosterone (THB) plus 5a-tetrahydrocorticosterone (5a-THB) to 11-dehydrotetrahydrocorticosterone (THA), and the plasma ratio of corticosterone to 11-dehydrocorticosterone.
Materials and methods

Supplies
Corticosterone, 11-dehydrocorticosterone, PAN and adriamycin were purchased from Sigma Chemical Co. (Buchs, Switzerland). Bicinchoninic acid protein assay reagent (BCA) was received from Pierce Chemical Co. (Rockford, IL, USA). The 5a-androstane-3a, 17a-diol, stigmasterol and cholesteryl butyrate were purchased from Steraloids (Wilton, NH, USA).
Experimental animals
The protocol was approved by the ethics committee at our institution. Male Wistar rats, weighing 200-230 g were kept in a temperature-, humidity-and light-controlled room (12-h light, 12-h dark cycle) and maintained on a normal chow diet without fluid restriction. Animals were kept in metabolic cages for urine collection. After an adaptation period of 4 days, the rats received either a single IP dose of PAN (15 mgu100g body weight in 1 ml of NaCl 0.9%) for the induction of proteinuria, or the solvent only (1 ml of NaCl 0.9%). Adriamycin nephrosis was induced by a single dose of 7.5 mgukg body weight, freshly prepared and diluted to 0.75 mgukg body weight into the tail vein w15-18x.
Steroid analysis by gas chromatography-mass spectrometry Analysis of corticosterone and 11-dehydrocorticosterone in plasma. For analysing corticosterone and 11-dehydrocorticosterone, 100 ng of 11a-tetrahydrocortisol was added to 1 ml of plasma as an internal standard, and the sample was extracted with 10 ml of dichlormethane on a rotator. After centrifugation at 30003 g for 5 min and separation of the phases, the organic layer (containing the unconjugated steroids) was evaporated under a stream of nitrogen at room temperature. The sample was derivatized to form the methyloxime-trimethylsilyl ethers. The excess derivatization reagent was removed by gel filtration on a Lipidex-5000 column. As an internal standard, 100 ng of 11a-tetrahydrocortisol was added to the water phase (containing the conjugated steroids). Plasma proteins were precipitated with 5 ml of methanol. After evaporation of the solvent, the sample was reconstituted in 0.1 M acetate buffer and hydrolyzed with 12.5 mg of powdered Helix pomatia enzyme (Sigma) and 12.5 ml of b-glucuronidaseu arylsulphatase (Roche, Basel, Switzerland) at 558C for 3 h. The hydrolysis mixture was extracted with a Sep Pak C18 column, and the resulting free steroids were derivatized to form the methyloxim-trimethylsilyl ethers. The excess derivatization reagent was removed by gel filtration on a Lipidex-5000 column.
Samples were analysed by gas chromatography-mass spectrometry using a Hewlett-Packard gas chromatograph 6890 equipped with a mass selected detector 5973 by selective ion monitoring. One characteristic ion was chosen for each of the compounds being measured. The ion number (muz) 548, 474 and 652, were chosen for corticosterone, 11-dehydrocorticosterone and 11a-tetrahydrocortisol, respectively. Calibration lines were established over the range of 5 nguml to 100 nguml. Correlation coefficients were )0.98. Coefficients of variation for intra-and inter-day analysis were -15%.
Analysis of steroid metabolites in urine. Urine sample preparation consists of pre-extraction, enzymatic hydrolysis, extraction from the hydrolysis mixture, derivatization and gel filtration w19x. Briefly, 2.5 mg of medroxyprogesterone was added to 1.5 ml of urine as recovery standard. The sample was extracted on a Sep-Pak C 18 column, dried, reconstituted in 0.1 M acetate buffer, adjusted to pH 4.6 and hydrolysed with powdered Helix pomatia enzyme (12.5 mg; Sigma) and 12.5 ml of b-glucuronidaseu arylsulphatase liquid enzyme (Roche, Basel, Switzerland). The resulting free steroids were extracted on a Sep-Pak C 18 cartridge. The mixture of internal standards (5a-androstane-3a, 17a-diol, stigmasterol, cholesteryl butyrate, 2.5 mg each) was added to this extract, and the sample was derivatized to form the methyloxime-trimethylsilyl ethers. One characteristic ion was chosen for each compound being measured. The ion number (muz) 564, was monitored for THB and 5a-THB, and 490, for THA. A temperature-programmed run from 210 to 2658C over 35 min was chosen. As a calibration standard, a defined steroid mixture of the measured steroid metabolites was analysed. The 'ion peak' abundance was quantified against the internal standard stigmasterol. Using this method the following metabolites were determined in urine: THB, 5a-THB and THA.
Analysis of data
Data were analysed by Student's paired two-tailed t-test. Results are given as mean"SEM.
Results
The urinary ratio of (THBq5a-THB)uTHA increased from day 0 to day 1 in all animals. Accordingly, the mean ratios increased from 1.41"0.12 to 2.25"0.25 (P-0.01) following the injection of PAN, and from 1.48"0.11 to 2.95"0.30 (P-0.05) following the injection of adriamycin (Figure 1 ). The increased ratios of (THBq5a-THB)uTHA were attributable to a decreased urinary excretion of THA in proteinuric animals. This effect is best shown by comparing the 24 h urinary excretion of THA as a function of THBq5a-THB. To illustrate, the results from days 0 and 3 ( Figure 2a ) and from days 12 and 18 ( Figure 2b ) in the PAN-and adriamycin-treated animals are shown. Analysis of plasma corticosteroneu11-dehydrocorticosterone ratios revealed an increase in both animal models (Figure 3) .
Compared with the increase in the urinary steroid metabolite ratio, the urinary protein excretion occurred later (Figure 1 ). On day 6 in the PAN group, and on day 9 in the adriamycin group, all six animals in each group had increased urinary protein excretion rates. The urinary sodiumupotassium ratio declined from 0.61"0.05 on day 0 to 0.43"0.03 on day 2 (P-0.05) in the PAN-treated animals, and from 0.48"0.03 on day 0 to 0.30"0.04 on day 4 (P-0.02) in the adriamycin-treated animals, indicating an enhanced mineralocorticoid effect.
Discussion
PAN and adriamycin induce proteinuria with avid renal salt retention and structural changes in the glomerulus and renal tubules, which is characteristic of minimal change glomerulopathy w15-17,20,21x. Therefore, these two models of experimental nephrotic syndrome in rats are widely used to investigate the mechanisms accounting for the nephrotic disease state. The time course for the appearance of proteinuria in our groups of animals given either PAN or adriamycin is in line with that observed in the literature w16,20,22x. Interestingly, in both models, the increase in the urinary ratio of (THBq5a-THB)uTHA was present before a significant urinary excretion of protein was observed (Figure 1 ). This observation might account for the hitherto unexplained finding that sodium retention occurs before the onset of proteinuria in PAN-and adriamycin-treated rats w15,16,22x. Such a dissociation between renal sodium retention and proteinuria is not restricted to these two models but has also been described in other situations, such as Heymann nephritis or serum sickness w23x.
The dissociation between the appearance of proteinuria and renal sodium retention is one of the arguments forwarded by the critics of the traditional view of renal sodium retention in nephrotic patients. Traditionally, the increased renal sodium retention in nephrotic patients has been attributed to a secondary hyperaldosteronism, as a consequence of renal hypoperfusion related to fluid sequestration w24x. This concept has been questioned, firstly, by the results from the above mentioned experimental models w16,20-23x and, secondly, by the observation that adrenalectomized rats injected with PAN develop a full-blown nephrotic syndrome w22x. Therefore, another mechanism for sodium retention in nephrotic subjects has to be postulated. An aldosterone-independent candidate mechanism is a reduced activity of 11b-HSD2, a characteristic which provides promiscuous access of glucocorticoids, such as cortisol or corticosterone, to the mineralocorticoid receptor w1,3,4x. The present observation of an increased urinary ratio of (THBq5a-THB)uTHA and an increased plasma ratio of corticosteroneu11-dehydrocorticosterone in rats with nephrotic syndrome, together with our previous finding of an increased urinary ratio of (THFq5a-THF)u THE in humans with proteinuria w4x, strongly supports the contention of a reduced renal 11b-HSD2 activity in this disease state.
Deschenes et al. w16x previously performed meticulous salt balance studies in rats with PAN-and adriamycin-induced nephrotic syndrome. They observed an early decrease in sodium excretion in PAN-treated animals starting on day 2, an observation in line with the decreased urinary sodiumupotassium ratio found in our rats treated with the same agent. Similarly, the effect was less pronounced in both studies when rats were given adriamycin w16x. These effects paralleled the decline in the apparent activity of 11b-HSD2, as assessed by the steroid metabolites. In both studies, the changes in the urinary electrolyte excretion preceded the appearance of proteinuria.
The increased urinary ratio of (THBq5a-THB)u THA presumably reflects a reduced activity of 11b-HSD2 and not of total 11b-HSD (i.e. 11b-HSD1 plus 11b-HSD2) activity, because in 11b-HSD1 knockout mice, which have a lack of functioning 11b-HSD1 enzyme, the urinary ratio of (THBq5a-THB)uTHA is not altered w25x. It has been proposed that the ratio of urinary corticosteroneudehydrocorticosterone in rodents, or cortisolucortisone in humans, may be more suitable for indicating the activity of renal 11b-HSD2 w26-29x. Recently, Ferrari et al. w30x , in an in depth analysis in human subjects with or without salt-sensitivity, have shown that the cortisolucortisone ratio does not appear to be more sensitive for detecting changes in 11b-HSD2 activity than (THFq5a-THF)u THE, which is the analogue of (THBq5a-THB)uTHA in rodents. Because of this controversy, we measured the corticosteroneu11-dehydrocorticosterone ratios as well as the (THBq5a-THB)uTHA ratios, in both animal models. Both measures point to a decreased 11b-HSD2 activity. Moore et al. w31x studied extrarenal localization of 11b-HSD2 expression in the mouse at the level of gene transcription, and found that 11b-HSD2 was expressed in the colon, small intestine, stomach and epididymus, in addition to renal tissue. Furthermore, expression of 11b-HSD2 has been found in human vascular smooth-muscle cells w32x. It is not known if inhibition of extra-renal 11b-HSD2 alters the urinary (THBq5a-THB)uTHA ratio in rats. In patients without renal 11b-HSD2 activity, inhibition of extra-renal activity by glycyrrhetinic acid resulted in an increased plasma ratio of cortisolucortisone w33x. However, the relevance of this finding for the urinary (THBq5a-THB)uTHA ratio is not known.
The mechanism for the early decline in the apparent 11b-HSD2 activity, assessed in vivo by measuring urinary glucocorticosteroid metabolites, in our PANand adriamycin-treated rats is unknown (Figure 1) . Two mechanisms have to be considered. Firstly, it is conceivable that the xenobiotics directly caused the decline of the apparent activity of 11b-HSD2. This is unlikely to be the case because, when we incubated cells expressing 11b-HSD2, no inhibitory effect of PAN or adriamycin was observed (unpublished observation). Secondly, a reduced 11b-HSD2 activity in vivo can occur in the presence of inhibitors. Morris et al. w34,35x observed glycyrrhetinic acid like factors (GALF) in urine from patients with hypertension or heart failure, indicating that these inhibitors of 11b-HSD activity are water soluble. In patients with cholestasis, bile acids reduce 11b-HSD2 activity which results in MR activation by cortisol w36x. Future studies must be carried out to define the GALF or other inhibitors that are presumably present in the nephrotic syndrome.
Ichikawa et al. w21x, in a seminal investigation using a unilateral model of PAN-induced albuminuria and micropuncture methodology, demonstrated that the enhanced sodium retention was only present in the proteinuric kidney and was clearly localized downstream of the distal tubule. Later on, in collaboration with H. Favre w20,22x, one of us showed that the Na,K-ATPase activity is significantly enhanced in the cortical collecting duct (CCT) from rats with PANinduced nephrotic syndrome. Vasopressin is known to stimulate Na,K-ATPase activity in the CCT w37x. Recently, Deschênes and Doucet w16x showed that ADH cannot account for the enhanced Na,K-ATPase activity in ADH-deficient Brattleboro rats treated with PAN. Thus, at the present time the best established factors for up-regulating the Na,K-ATPase in the CCT remain mineralo-or gluco-corticosteroids w38,39x. A decreased activity of 11b-HSD has been shown to enhance the intracellular availability of corticosteroids to the cognate receptor w4,6x. Furthermore, Biller et al. w11x recently showed direct in vivo evidence for a reduction in fractional sodium excretion during inhibition of 11b-HSD2 in the collecting duct. Therefore, the present observation of increases in (THBq5a-THB)uTHA ratios in urine, and in corticosteroneu11-dehydrocorticosterone ratios in plasma, suggests that a reduced activity of 11b-HSD2 contributes to the abnormal sodium retention in the animal models investigated. This observation is supported by the decrease in the urinary sodiumu potassium ratio shortly after the administration of the xenobiotics for the induction of the nephrotic syndrome, indicating increased mineralocorticoid activity.
In conclusion, the previous observations in patients with the nephrotic syndrome w14x and the present study in two well established animal models indicate that the activity of 11b-HSD2, assessed by the urinary (THBq5a-THB)uTHA ratio, is reduced in nephrotic syndrome. These observations suggest that endogenous glucocorticoids exhibit a mineralocorticoid effect and contribute to abnormal sodium retention in nephrotic syndrome.
